7-year extension data from an RCT in rheumatoid arthritis with inadequate methotrexate response: upadacitinib showed TEAE rates comparable to adalimumab, with numerically more herpes zoster, CPK elevation, non-melanoma skin cancer and lymphopenia; responses were maintained.
RCT
Fleischmann et al. Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study